Figures & data
Figure 1 Plasma levodopa profiles with conventional levodopa dosing strategies. Schematic depicting plasma levodopa levels in Parkinson’s disease patients experiencing re-emergence of symptoms due to wearing-off achieved by (A) increasing the daily levodopa/carbidopa dose from 300 mg/day to 450 mg/day; (B)increasing the frequency of levodopa/carbidopa dosing from 3 times/day to 5 times/day.
![Figure 1 Plasma levodopa profiles with conventional levodopa dosing strategies. Schematic depicting plasma levodopa levels in Parkinson’s disease patients experiencing re-emergence of symptoms due to wearing-off achieved by (A) increasing the daily levodopa/carbidopa dose from 300 mg/day to 450 mg/day; (B)increasing the frequency of levodopa/carbidopa dosing from 3 times/day to 5 times/day.](/cms/asset/a717ced2-4a88-46a1-b439-91feab1d66c7/dndt_a_1660_f0001_b.jpg)
Figure 2 Plasma levodopa profile with levodopa/carbidopa/entacapone versus levodopa/carbidopa. Treatment with levodopa/carbidopa/entacapone 3 times/day significantly improves troughs in plasma levodopa levels compared with equivalent doses of levodopa/carbidopa in patients with Parkinson’s disease; *p < 0.05; †p < 0.01; ‡p < 0.001; SEM, standard error of the mean.
![Figure 2 Plasma levodopa profile with levodopa/carbidopa/entacapone versus levodopa/carbidopa. Treatment with levodopa/carbidopa/entacapone 3 times/day significantly improves troughs in plasma levodopa levels compared with equivalent doses of levodopa/carbidopa in patients with Parkinson’s disease; *p < 0.05; †p < 0.01; ‡p < 0.001; SEM, standard error of the mean.](/cms/asset/d1270b06-a090-47d8-a8e8-e4c9b7093655/dndt_a_1660_f0002_b.jpg)
Figure 3 Efficacy of levodopa/dopa decarboxylase inhibitor and entacapone therapy in the short-term. Treatment with levodopa/DDCI and entacapone is associated with significant improvements in functional control as determined by UPDRS total, ADL and motor scores compared with levodopa/DDCI and placebo over 6 months. *p < 0.01; †p < 0.05.
![Figure 3 Efficacy of levodopa/dopa decarboxylase inhibitor and entacapone therapy in the short-term. Treatment with levodopa/DDCI and entacapone is associated with significant improvements in functional control as determined by UPDRS total, ADL and motor scores compared with levodopa/DDCI and placebo over 6 months. *p < 0.01; †p < 0.05.](/cms/asset/97dbdde1-a7a6-49a5-8ff6-3995799e7aeb/dndt_a_1660_f0003_b.jpg)
Table 1 Most frequent adverse events associated with levodopa/dopa decarboxylase inhibitor and entacapone therapy
Figure 4 Efficacy of levodopa/dopa decarboxylase inhibitor and entacapone therapy in the long-term. Functionality is maintained over three years with levodopa/DDCI and entacapone.
‡p =not significant.
![Figure 4 Efficacy of levodopa/dopa decarboxylase inhibitor and entacapone therapy in the long-term. Functionality is maintained over three years with levodopa/DDCI and entacapone.‡p =not significant.](/cms/asset/c559529a-4c73-4ac2-92b8-3956e71e705d/dndt_a_1660_f0004_b.jpg)
Figure 5 Effect of levodopa/carbidopa/entacapone on quality of life in patients with stable Parkinson’s disease. Treatment with levodopa/carbidopa/entacapone is associated with significant benefits in terms of quality of life compared with levodopa/carbidopa, as determined by the Parkinson’s disease questionnaire-8.
![Figure 5 Effect of levodopa/carbidopa/entacapone on quality of life in patients with stable Parkinson’s disease. Treatment with levodopa/carbidopa/entacapone is associated with significant benefits in terms of quality of life compared with levodopa/carbidopa, as determined by the Parkinson’s disease questionnaire-8.](/cms/asset/eda7c715-bf60-44b1-8a32-715af488bb30/dndt_a_1660_f0005_b.jpg)